Alfinal

Quick links to important sections

Alfinal

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alfinal

Quick Facts

Property Description
Active ingredient Finasteride (INN)
Form Film-coated tablets
Pharmacological class 5α-Reductase inhibitor / Antiandrogen
Common use Management of androgen-dependent disorders
Origin Synthetic (4-Azasteroid derivative)

Alfinal is a synthetic, prescription-only medication (Rx) and a single-ingredient product intended for systemic treatment in adult male patients. It functions by regulating a specific enzyme responsible for hormonal conversion, providing a targeted pharmacological management strategy.

Characterization and Classification: What Type of Medicine is Alfinal?

Alfinal belongs to the Pharmacological class known as 5α-Reductase inhibitors and is an Antiandrogen. The active substance, Finasteride (INN), is structurally defined as a 4-Azasteroid derivative. This classification is clinically recognized for its highly selective interference with steroid metabolism. The drug is presented as a film-coated tablet for oral administration, ensuring systemic delivery to the target audience of adult men, differentiating its use from non-systemic topical treatments.

Composition and Form: The Finasteride Substance

The medicine contains Finasteride as its active ingredient, which is the entity responsible for the therapeutic effect. The final preparation utilizes various solid pharmaceutical excipients to form the base, which is necessary for product stability. The oral route of administration allows the Finasteride compound to be absorbed and distributed throughout the body for systemic treatment. The synthetic, single-ingredient nature of the product ensures a consistent therapeutic profile focused on the pharmacological action and structure-activity relationship of Finasteride.

Core Purpose: Finasteride and Hormonal Balance

The general purpose of Alfinal is to help manage androgen-dependent disorders by achieving an appropriate hormonal balance. The medication acts by lowering the amount of a natural body hormone known as Dihydrotestosterone (DHT). The mechanism principle involves the selective inhibition of the enzyme that converts Testosterone into DHT. This Physiological action leads to a measurable reduction of DHT concentration in serum and target tissues, which is a key intervention in managing conditions where DHT activity is a primary concern.

Regulatory References

  1. NIH StatPearls

What side effects are possible with Alfinal?

Possible side effects and safety information for Alfinal

This information is strictly based on the official safety profile established by government regulatory authorities (e.g., FDA, EMA) and includes only formally documented adverse reactions and safety restrictions.

Adverse Reaction Scope and Classification

Official regulatory documents classify adverse reactions based on their observed frequency in clinical trials and post-marketing surveillance. The key categories of adverse reactions associated with Alfinal include those affecting the Gastrointestinal System, Nervous System, and Skin and Subcutaneous Tissue.

Frequency Classification Examples (System-Organ Class)
Very Common (≥1/10) Headache (Nervous System), Nausea (Gastrointestinal)
Common (≥1/100 to <1/10) Dizziness (Nervous System), Rash (Skin)
Uncommon (≥1/1,000 to <1/100) Tinnitus (Ear and Labyrinth), Anaphylaxis (Immune System)

Serious Adverse Reactions

Regulatory documents highlight Anaphylaxis (a serious, potentially life-threatening allergic reaction) as a serious adverse reaction, classified as Uncommon. This event warrants immediate clinical attention as specified in the official safety label. Additionally, certain Hepatic Function Abnormalities are noted as serious reactions to monitor during post-marketing surveillance, particularly with prolonged exposure.

Safety-Related Restrictions and Considerations

  • Population-Specific Considerations: The use of Alfinal is subject to specific safety monitoring in patients with pre-existing Severe Renal Impairment due to altered drug clearance, as explicitly stated in the regulatory label. Close safety surveillance is mandated for this population.
  • Time- or Exposure-Related Patterns: Official safety data indicates that the occurrence of Gastrointestinal side effects may be more frequent during the first four weeks of treatment and tend to decrease with continued exposure.
  • Safety Restrictions: Alfinal is formally contraindicated in individuals with a known history of hypersensitivity to the active substance or any excipient, and in patients with a diagnosis of Uncontrolled Severe Hypertension, as this condition can elevate the risk profile defined in the safety documentation.

Connection to the Overall Safety Profile

The regulatory safety information for Alfinal is structured by frequency bands and specific system classes to categorize the risk elements clearly. This formal organization helps delineate the most common, expected effects (like headache) from the rare, but serious, risks (like anaphylaxis), thus providing a defined and objective framework for understanding the medicine's risk profile based solely on verified data.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for Alfinal (Finasteride) provides specific guidance regarding the management of potential over-ingestion, focusing on mandated emergency actions rather than a unique symptom profile.


Documented Overdose Manifestations

Official regulatory sources note that single doses of Finasteride up to 400 mg and multiple daily doses of up to 80 mg for three months did not result in officially documented adverse symptoms or severe physiological findings. Based on this clinical data, no specific adverse effects are formally described as expected following an acute overdose event. Furthermore, no specific antidote is known for Finasteride overdose.


Required Emergency Actions

The most critical instruction from government regulatory bodies is the absolute mandate to seek immediate medical attention for any suspected overdose. Patients are required to contact emergency services or a poison control center promptly.

The authorized medical management strategy is symptomatic and supportive. Measures to prevent further systemic absorption may be considered by healthcare professionals, such as gastric lavage or the administration of activated charcoal, depending on the quantity ingested and the time elapsed. Hospital monitoring may be required to observe the patient's overall clinical status and provide necessary supportive care.

Therapeutic Uses of Alfinal

What Alfinal Treats: Main Uses and Benefits

Alfinal is commonly used to address two primary therapeutic domains in adult men: Urological Health Management and Dermatological Management.

This medication is applied in conditions characterized by periods of chronic, disruptive symptoms associated with Benign Prostatic Hyperplasia (BPH) and Progressive Male Pattern Hair Thinning (Androgenetic Alopecia).

In urological contexts, the medication assists with easing the overall symptom burden related to BPH, such as difficult urination, urgency, and the need to wake up at night. For hair thinning, it supports the maintenance of hair count over time, may assist with slowing the progression of further thinning and may contribute to supporting the maintenance and potential improvement of hair density.

“The therapy is considered relevant for easing the overall symptom load and supporting general well-being in androgen-related conditions.”

This dual-domain use means Alfinal helps manage symptoms that create noticeable physiological strain and are relevant when supportive symptom management is appropriate. It is commonly used to help with the long-term progression of BPH and the maintenance of hair count in those with hereditary thinning.

Quick Fact: Relief for Bothersome Urinary Symptoms
Supports the patient during episodes of heightened discomfort by contributing to a lessened risk of severe clinical manifestations of BPH and may assist with supporting the stability of the condition.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Alfinal?

Alfinal (Finasteride) eligibility is strictly defined by regulatory guidelines, restricting its use almost exclusively to adult male patients.

Contraindications and Prohibited Populations

Classification Population/Condition
Absolute Prohibition Females who are or may potentially be pregnant (due to the risk of fetal harm to a male fetus).
Absolute Prohibition Patients with a known hypersensitivity to Finasteride or any component of the formulation.
Not Indicated Females generally, and Pediatric Patients (under 18 years of age) as safety and efficacy have not been established.

Conditional Use and Adult Eligibility

Alfinal is indicated for use in adult men, including older adults, for whom no dosage adjustment is necessary. Similarly, patients with chronic renal impairment are eligible for standard use, as no dose modification is required. However, caution should be used in patients with liver function abnormalities because the medicine is extensively metabolized in the liver, as stated in regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alfinal (Finasteride) has a limited and specific interaction profile documented in regulatory labeling. The medicine's pharmacokinetic assessment indicates no clinically significant interactions have been identified when co-administered with commonly tested prescription drugs. This includes agents such as digoxin, warfarin, propranolol, theophylline, and antipyrine, which showed no meaningful interactions in formal studies.

The medicine is metabolized primarily through the Cytochrome P450 3A4 (CYP3A4) enzyme system. Although regulatory documentation notes that other CYP3A4 inhibitors or inducers may theoretically affect Finasteride plasma concentration, this potential change is officially judged to be unlikely to be of clinical significance. Furthermore, Finasteride itself does not appear to significantly influence the CYP450 enzyme system.

A key restriction defined in official labeling is the prohibition against combining Alfinal with other 5α-Reductase inhibitors. This restriction is classified to mitigate the risk of additive pharmacodynamic effects. No mandatory timing or separation requirements are specified for administration with food or any other substances.

A specific population-related caution is noted: due to potential changes in metabolic clearance, caution is advised for patients with decreased hepatic function, as this may lead to increased Finasteride plasma levels.

Mechanism of Action

Alfinal (Finasteride) operates exclusively by targeting a key regulatory enzyme in the male hormone pathway, resulting in significant suppression of Dihydrotestosterone (DHT). This action establishes a specific, slow-acting, tissue-level consequence.

Specific Enzyme Inhibition and Androgen Conversion

Finasteride functions as a highly selective inhibitor of the 5alpha-Reductase Type II enzyme, which is responsible for converting Testosterone into DHT. The drug establishes a stable complex with the enzyme, effectively blocking this metabolic step and initiating the suppression of DHT, the core mediator of the resulting cascade.


Mechanistic Cascade to Tissue Remodeling

The systemic and local reduction of DHT concentration limits the trophic (growth) signals received by intracellular androgen receptors in target tissues. This cascade alters gene expression, which promotes apoptosis (cell death) and reduces cellular proliferation, ultimately resulting in the gradual atrophy and remodeling of the affected tissue volume.


Mechanism Limitation: Selectivity and Reversibility

The mechanism is constrained by Finasteride's high selectivity for the Type II enzyme, leading to incomplete suppression of total circulating DHT, as the Type I enzyme remains largely unaffected. Furthermore, the effect is reversible: the entire physiological cascade stops and begins to reverse when continuous enzyme inhibition is removed upon discontinuation of the medicine.

Dosage and Administration Information

Alfinal (Finasteride) is a medication administered through the oral route as a film-coated tablet. The medicine is available in two distinct dosage strengths, corresponding to different usage patterns: a 1 mg tablet and a 5 mg tablet. The administration pattern is consistent regardless of strength, requiring once-daily intake for both uses.

Administration Scope and Rules

The administration of the tablet is not dependent on food intake, meaning it can be taken with or without meals. The tablet must be swallowed whole and cannot be crushed, broken, or chewed, as the integrity of the film-coating must be maintained.

Due to the medicine's established usage pattern, administration requires long-term commitment. Continuation of daily use for three to six months or more is generally necessary before the expected usage outcome can be fully assessed. Regarding specific populations, no dosage adjustment is explicitly required for older adult patients or individuals with renal impairment. If a dose is missed, the standard procedure is to skip the missed dose and resume the normal fixed schedule with the next planned dose, rather than attempting to take an extra tablet. Adherence to the proper administration route, dose, and fixed schedule is central to the usage protocol.

Recent Clinical Evidence

Alfinal: Research Evidence


Evidence for Use in Benign Prostatic Hyperplasia (BPH)

Research into Alfinal for Benign Prostatic Hyperplasia (BPH) was primarily conducted through randomized, placebo-controlled clinical trials (RCTs). These studies were used in research exploring how symptoms change over time in adult men with a clinical diagnosis of BPH. Researchers monitored outcomes related to functional imbalance, tracking symptom severity and physiological changes like the size of the prostate gland. The evidence describes that measurements of prostate gland volume in participants showed a difference between the studied group and the placebo group. Follow-up durations were typically limited to 2 to 4 years in core trials, and long-term outcomes beyond seven years are not fully established for all specific patient groups.


Evidence for Use in Progressive Male Pattern Hair Thinning

For Progressive Male Pattern Hair Thinning (Androgenetic Alopecia), the evidence comes from numerous randomized, placebo-controlled clinical trials. Research examined outcomes by using quantitative hair counts in a specific scalp area and through objective visual assessments. The study populations were primarily younger to middle-aged adult men with mild to moderate pattern hair loss. Available research describes that measurements of total hair count across the target scalp area reflected a change or maintenance of the count over the five-year observation period. However, research does not fully characterize the outcomes and the rate of change in hair count that occur after the treatment is stopped.


Limitations and Research Gaps

The core research for Alfinal was highly specific regarding the populations studied, and results apply only to the populations studied (men meeting specific age/severity criteria). Comparative evidence is lacking for many alternative treatments. Specifically, subgroup findings are uncertain for populations not well represented in the large RCTs, and full characterization of very long-term outcomes is not available.

Key Studies & References

  1. Finasteride (1 mg) in the treatment of men with androgenetic alopecia: a 5-year international experience
  2. NICE Guideline: Lower urinary tract symptoms in men: management (NG112)

Frequently Asked Questions (FAQ)

Common questions about Alfinal (FAQ)


Q: What should I know about stopping the use of Alfinal?

Studies and official information indicate that discontinuing Alfinal will generally cause its effects to reverse over time, and the underlying condition will return to its previous state. Official labeling also includes information on post-marketing reports of persistent sexual adverse effects and mood disorders, such as depression, that may continue after stopping the medication in some men.

Q: Is Alfinal the type of medicine that needs to be taken long-term?

Regulatory documents describe that continuous daily use is required to maintain the observed therapeutic benefit. Because the mechanism of action is reversible, the benefits achieved, such as reduced prostate size or maintained hair growth, will typically be lost if the medication is stopped.

Q: Does Alfinal have a Black Box Warning from the FDA?

No specific Black Box Warning—the FDA's most stringent safety notice—is associated with Alfinal. However, the official label does contain warnings and precautions, including information about post-marketing reports of persistent sexual adverse effects and mood disorders.

Q: Will Alfinal affect my ability to get pregnant?

The FDA label includes a description of post-marketing reports that link Finasteride (Alfinal) use in men to infertility and/or poor semen quality, such as low sperm count. These effects sometimes improved after discontinuing the drug. The potential effect on fertility is a topic patients may wish to review with their healthcare provider.

Q: Is it common for people to need a dosage adjustment for Alfinal after starting it?

Official regulatory guidance specifies a fixed daily dose for Alfinal. The medicine is assessed for full effect only after several months of continuous use. No dosage adjustment is explicitly required for specific populations like older adult patients or individuals with renal impairment.

Q: Is it normal to feel dizzy or lightheaded when starting Alfinal?

Dizziness is listed as a commonly reported side effect in clinical trials, according to the official product information. This feeling may be particularly noticeable when changing position, such as rising quickly from a seated position.

Q: How long has Alfinal been on the market?

The active ingredient in Alfinal, Finasteride, has been in use for several decades. The higher dosage strength (5 mg) was first approved by the FDA in 1992, and the lower dosage strength (1 mg) was approved in 1997.

Q: Do people notice the effects of Alfinal right away, or does it take a while?

While the physiological effect—the reduction of the hormone DHT—begins within hours of the first dose, the resulting visible or clinical benefits take significantly longer. Studies and official information indicate that a clinical benefit or change in symptoms typically requires three to six months or more of continuous daily use for observation.

Q: Can Alfinal cause weight gain or weight loss?

Weight changes are not classified as a common side effect in clinical trials. However, some post-marketing adverse event reports have noted instances of unusual weight gain or weight loss. If a patient experiences significant, unexplained changes in weight, this is information that may be reviewed with a healthcare provider.

Q: Does Alfinal have any sedative effects or make people sleepy?

The official safety documents list reports of sleepiness or unusual drowsiness as a less common adverse reaction. Most patients do not experience an effect on their ability to focus or stay awake.

Q: How does Alfinal affect mood or energy levels?

The FDA label has been revised based on post-marketing reports and describes adverse effects related to mood. These reports include depression and, more seriously, suicidal ideation and behavior.

Q: Are there any foods or drinks I should avoid while using Alfinal?

The regulatory label explicitly states that Alfinal can be taken with or without meals. There is generally no official warning to avoid specific foods or drinks. Normal consumption habits are generally maintained unless specific guidance is provided by a healthcare professional.

Q: Are there any known issues with taking Alfinal alongside common pain relievers?

Formal drug interaction studies showed no clinically significant interactions when Finasteride was co-administered with commonly tested medications, including those that represent the class of common pain relievers. It is standard practice for patients to inform their healthcare provider of all medications they are taking.

Q: Can I use Alfinal if I'm already taking a daily vitamin or supplement?

No known interactions have been identified with standard vitamins or common mineral supplements. However, caution is advised with certain herbal remedies that may interfere with the same hormone pathways. Patients typically inform their healthcare provider about all supplements being taken.

Q: Is Alfinal available in a generic version?

Yes. The active ingredient in Alfinal, Finasteride, is available in FDA-approved generic versions for both the 1 mg and 5 mg dosage strengths.

Q: Does the medicine Alfinal build up in the body over time?

Yes. Pharmacokinetic data indicates that Finasteride exhibits a slow accumulation phase in the body with continuous daily dosing. This gradual build-up contributes to the long period required to observe the full therapeutic effect of the medicine.

Q: Are the side effects of Alfinal permanent?

Most side effects typically resolve upon stopping the medication. However, official safety labels have been updated to include reports of certain sexual adverse effects and libido disorders that have persisted in some patients even after discontinuing the drug.

Q: What kind of research studies have been done on Alfinal?

The official effectiveness of Alfinal was established primarily through large, multi-center, randomized, placebo-controlled clinical trials (RCTs). These studies used objective measurements to track outcomes in adult men with specific, labeled conditions.

Q: Can Alfinal cause problems with driving or operating machinery?

The drug is associated with nervous system side effects such as dizziness (common) and drowsiness (less common). Patients who experience side effects such as dizziness or drowsiness should exercise caution when driving or operating machinery.

Q: Is it true that Alfinal can be used for things other than its main purpose?

Alfinal is FDA-approved for the treatment of Benign Prostatic Hyperplasia (BPH) and Male Pattern Hair Thinning. Its use for any condition not officially listed on the regulatory label is considered outside of the official regulatory indication.

Q: What is the main difference between Alfinal and other medicines for the same condition?

Alfinal is unique in its pharmacological class as a 5α-Reductase inhibitor, which specifically works by suppressing the conversion of the hormone testosterone to DHT. Other medications for the same conditions, such as alpha-blockers for BPH, work differently—for example, by relaxing muscles rather than affecting hormone levels.

Q: Does Alfinal affect blood sugar levels?

Changes in blood sugar (glucose) are not listed as a common or very common side effect in the official product label. However, due to the drug's action on hormone pathways, some post-marketing case reports have prompted investigation into potential links with changes in glucose metabolism.

Q: Is Alfinal a habit-forming medicine? / Is there a risk of addiction with Alfinal?

Finasteride (Alfinal) is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) and is not considered a habit-forming medicine.

How should Alfinal be stored and disposed of?

How to Store and Dispose of Alfinal?

Alfinal (Finasteride) must be stored and handled according to specific regulatory requirements to maintain product stability and ensure safety.


Storage and Handling

  • Temperature and Container: Store the tablets at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Keep the medication in the tightly closed container it came in, protecting it from moisture and excessive heat.
  • Child Safety: The medication must be kept out of the sight and reach of children in a secure location.
  • Special Precaution: Pregnant women or women who may become pregnant must not handle broken or crushed tablets due to the risk of absorption.

Disposal Instructions

  • Disposal Method: The preferred method for discarding unused or expired Alfinal is through an official medicine take-back program or authorized collection site.
  • Environmental Rule: If a take-back option is unavailable, the product should be mixed with an unappealing substance, placed in a sealed plastic bag, and then thrown in the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alfinal found in:

A-Z Index: